YOUR CONDITION, EXPLAINED
Soft Tissue Sarcoma (of Vascular Origin) VA disability rating & claim guide
The VA rates Soft Tissue Sarcoma (of Vascular Origin) under diagnostic code 7123, in 38 CFR § 4.104 (cardiovascular system), and the schedule provides a single evaluation under it: 100%.
Free · No account needed
Save your Soft Tissue Sarcoma (of Vascular Origin) guide
Email yourself this Soft Tissue Sarcoma (of Vascular Origin) guide so the rating criteria, evidence checklist, and preparation tips are easy to find later.
A CLEARER PATH FORWARD
Make sense of your next step.
01Understand the rating02Know what to gather03Plan your preparationTHE ESSENTIALS
How the VA rates Soft Tissue Sarcoma (of Vascular Origin)
DC 7123 covers soft tissue sarcoma of vascular origin — a cancer arising in blood vessel tissue. The code has one evaluation and one only: 100 percent. Its Note keeps that 100 percent in place beyond the end of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, and sets a mandatory VA examination six months after that treatment is discontinued. If there has been no local recurrence or metastasis by then, the evaluation is made on the residuals that remain.
DC 7123 has one criterion and one percentage: soft tissue sarcoma (of vascular origin) is evaluated at 100 percent. There are no lower bands and no measurements — nothing about the size or site of the tumor, and nothing about swelling, infections, or response to therapy. The code's Note governs everything that follows treatment. A rating of 100 percent continues beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating is determined by mandatory VA examination, and any change in evaluation based upon that or any subsequent examination is subject to the provisions of § 3.105(e). If there has been no local recurrence or metastasis, the evaluation is made on residuals. The code does not itself name which residuals or which codes they are evaluated under; what it fixes is the 100 percent while the disease is active and through treatment, the six-month mandatory examination once treatment stops, and the switch to residuals where there has been no local recurrence or metastasis.
- Diagnostic code
- 7123
- Rating schedule
- 38 CFR § 4.104
- Schedule levels
- 100%
How does the VA choose a rating level?
There is no higher or lower step inside this code: a rating decision either finds its criteria met or it does not. Where they are not met, 38 CFR § 4.31 assigns a 0% evaluation: service connection granted, at a level that does not pay.
EXPLORE THE PERCENTAGES
Soft Tissue Sarcoma (of Vascular Origin) VA rating criteria (DC 7123)
This condition has one published rating level. Read the criteria, then explore the details and monthly pay.
These are published rating criteria. Selecting a level does not predict your VA decision.
IN THE REGULATION’S OWN WORDS
What 38 CFR also says about Soft Tissue Sarcoma (of Vascular Origin)
The notes 38 CFR Part 4 prints with these criteria, quoted. They govern how the evaluation is made without being a rating level themselves.
- “Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.”DC 7123
BUILD YOUR EVIDENCE, ONE PIECE AT A TIME
Evidence for your Soft Tissue Sarcoma (of Vascular Origin) claim
A long list feels easier when you have a place to start. Use this checklist to see what you have and what still needs gathering.
Check off what you’ve gathered. Progress stays on this page until you leave or refresh.
THE EXAM FORM
Which DBQ is used for Soft Tissue Sarcoma (of Vascular Origin)?
VA publishes its questionnaires by body system; find the one for this condition on VA's list.
Source: VA: Public Disability Benefits Questionnaires (DBQs), read September 18, 2026.
SMALL DETAILS. BETTER PREPARATION.
Preparing your Soft Tissue Sarcoma (of Vascular Origin) claim
Start with the practical tips, then explore the common oversights. You don’t need to work through everything at once.
Practical tips for your claim4 tips
- 01
Keep the date treatment was discontinued clearly documented — surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure — since the Note runs the six months to the mandatory VA examination from that point.
- 02
Have oncology follow-up address local recurrence and metastasis in so many words. That finding is the dividing line between the 100 percent continuing and the evaluation moving to residuals.
- 03
Build the post-treatment record around what remains after the sarcoma and its treatment. Once the mandatory examination has been held and there has been no local recurrence or metastasis, residuals are what the evaluation rests on.
- 04
Expect the evaluation to be revisited rather than fixed: the Note makes any change based on that examination, or any subsequent one, subject to the provisions of § 3.105(e).
C&P exam pitfalls to keep in mind4 tips
- 01
Reaching the six-month mandatory examination with no post-treatment workup in the file, leaving the examiner nothing to assess residuals on.
- 02
A record that documents the sarcoma and its treatment but never states whether there has been local recurrence or metastasis, which is the fact the Note turns on.
- 03
Treatment dates left vague, so the six months after discontinuance of treatment cannot be fixed from the record.
- 04
Residuals described only in relation to the cancer, with no account of the specific functions affected, when the evaluation after the mandatory examination is made on residuals.
Common filing mistakes4 tips
- 01
Treating the 100 percent as permanent. The Note continues it beyond the cessation of treatment, but sets a mandatory VA examination six months after treatment is discontinued, with any change subject to § 3.105(e).
- 02
Letting the file go quiet once treatment ends, leaving no residual documentation for the examination the Note schedules.
- 03
Filing this as a swelling or lymphatic claim. DC 7123 is a malignancy code and its sole criterion is soft tissue sarcoma of vascular origin, evaluated at 100 percent.
- 04
Assuming the sarcoma diagnosis continues to control after the mandatory examination, when the Note directs the evaluation to residuals where there has been no local recurrence or metastasis.
When symptoms may first appear2 tips
- 01
The schedule follows a fixed sequence for this code rather than a symptom progression: the sarcoma is evaluated at 100 percent, treatment ends, the 100 percent continues beyond the cessation of that treatment, a mandatory VA examination falls six months after discontinuance, and the evaluation then rests on residuals if there has been no local recurrence or metastasis.
- 02
Where there has been no local recurrence or metastasis, residuals carry the evaluation from that point forward, so the findings recorded after treatment — not the sarcoma diagnosis itself — determine the percentage.
THE BROADER PICTURE
Soft Tissue Sarcoma (of Vascular Origin) by the numbers
- Veterans service-connected
- ~300 veterans
Vetrify editorial estimates informed by VA published claims data (VBA Annual Benefits Report) and the VA rating schedule, not official VA statistics.
LET’S CLEAR A FEW THINGS UP
Common questions about Soft Tissue Sarcoma (of Vascular Origin)
Is Soft Tissue Sarcoma (of Vascular Origin) a VA-rated disability?
Yes. The VA rates Soft Tissue Sarcoma (of Vascular Origin) under VASRD diagnostic code 7123 (Cardiovascular System). DC 7123 covers soft tissue sarcoma of vascular origin — a cancer arising in blood vessel tissue. The code has one evaluation and one only: 100 percent. Its Note keeps that 100 percent in place beyond the end of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, and sets a mandatory VA examination six months after that treatment is discontinued. If there has been no local recurrence or metastasis by then, the evaluation is made on the residuals that remain.
What VA disability rating can I get for Soft Tissue Sarcoma (of Vascular Origin)?
Possible VA ratings for Soft Tissue Sarcoma (of Vascular Origin) are 100%, 0%. The 0% level comes from 38 CFR 4.31, which assigns it wherever no compensable level is met. Examples: 100%: Soft tissue sarcoma (of vascular origin). Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.
What evidence helps prove Soft Tissue Sarcoma (of Vascular Origin) for VA disability?
Strong evidence for a Soft Tissue Sarcoma (of Vascular Origin) claim includes: Pathology reports establishing the diagnosis of soft tissue sarcoma and its vascular origin, which is what DC 7123 is written for; Oncology treatment records showing the dates of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, and the date treatment was discontinued; Follow-up imaging and oncology notes stating whether there has been local recurrence or metastasis; Operative reports documenting what was removed or reconstructed, which is what any residual impairment is built from.
What mistakes should veterans avoid when claiming Soft Tissue Sarcoma (of Vascular Origin)?
Common pitfalls when filing for Soft Tissue Sarcoma (of Vascular Origin): Treating the 100 percent as permanent. The Note continues it beyond the cessation of treatment, but sets a mandatory VA examination six months after treatment is discontinued, with any change subject to § 3.105(e); Letting the file go quiet once treatment ends, leaving no residual documentation for the examination the Note schedules; Filing this as a swelling or lymphatic claim. DC 7123 is a malignancy code and its sole criterion is soft tissue sarcoma of vascular origin, evaluated at 100 percent; Assuming the sarcoma diagnosis continues to control after the mandatory examination, when the Note directs the evaluation to residuals where there has been no local recurrence or metastasis.
Official sources
- 38 CFR § 4.104, Schedule of ratings, cardiovascular system (Diagnostic Code 7123)
- 38 CFR § 4.31, zero percent evaluations
Criteria in quotation marks are the regulation’s own words; everything else on this page is Vetrify’s summary of it. The eCFR text is authoritative. See how Vetrify derives its numbers.
How these figures are checked: our methodology and the open dataset.
VA Calc: Disability Pay
Combine your ratings & see monthly pay on your iPhone · Works offline